The global Gene
Therapy market is foreseen to grow by 20.1%, from USD 6.95 Billion in 2022 to
USD 30.16 Billion in 2030. High incidence of cancer and other target diseases,
product approvals, funding for gene therapy research is to drive the market for
the upcoming forecast period. However, high treatment costs remains one factor
hindering the market growth over the anticipated period.
Market Definition
Gene Therapy refer to any materials, instruments, or
equipment that are used in the diagnosis, treatment, or prevention of illnesses
or injuries. These supplies can include a wide range of products, from bandages
and dressings to complex medical devices and equipment.
Gene Therapy refer to equipment, devices, and
other consumables used by medical professionals to diagnose, treat, and prevent
diseases or injuries. These products range from simple bandages and syringes to
complex machinery like MRI machines and surgical robots. Gene Therapy are an
essential part of the healthcare industry and are crucial in providing quality
medical care to patients.
Market Overview
Gene Therapy:
The Future of Medicine
Gene therapy is
an innovative field of medicine that is rapidly gaining momentum in the
healthcare industry. It is a technique that involves the delivery of genetic
material into a patient's cells to treat or prevent diseases. This approach is
promising because it addresses the underlying cause of a disease, rather than
simply treating its symptoms. This essay will explore the potential of gene
therapy and how it works, as well as its benefits and challenges.
How Gene Therapy Works
Gene therapy
works by introducing new genetic material into a patient's cells. This genetic
material can be a functional copy of a missing or defective gene, or it can be
a new gene that produces a therapeutic protein. There are two main types of
gene therapy: in vivo and ex vivo.
In vivo gene
therapy involves delivering the genetic material directly to the patient's
cells in their body. This can be done through a variety of methods, such as
injection, infusion, or inhalation. Ex vivo gene therapy involves removing
cells from the patient, modifying them in the lab, and then returning them to
the patient's body. This method is often used when a patient's cells need to be
edited or modified before being returned to the body.
Benefits of Gene Therapy
One of the
biggest benefits of gene therapy is its potential to cure genetic disorders
that were previously untreatable. Diseases like cystic fibrosis, sickle cell
anemia, and Huntington's disease can all be treated with gene therapy.
Additionally, gene therapy can also be used to treat non-genetic diseases like
cancer, heart disease, and HIV. Gene therapy is also a potential cure for many
rare diseases that affect a small number of people.
Another benefit
of gene therapy is that it can be a one-time treatment. Unlike traditional
medicines, which often require daily or weekly doses, gene therapy can provide
a long-lasting cure. This can save patients time and money, as well as reduce
the burden on healthcare systems.
Challenges of Gene Therapy
While gene
therapy has the potential to revolutionize medicine, there are still several
challenges that need to be addressed. One of the main challenges is the
delivery of the genetic material to the patient's cells. The genetic material
needs to be delivered to the right cells and in the right amount. This can be
difficult, especially if the patient has a large number of cells that need to
be modified.
Another
challenge is the potential for unintended consequences. The genetic material
that is introduced into the patient's cells could have unintended effects. For
example, it could disrupt other genes or trigger an immune response.
Additionally, gene therapy is still a relatively new field, and there is much
that is still unknown about its long-term effects.
Conclusion
Gene therapy is
a promising field of medicine that has the potential to revolutionize how we
treat diseases. It offers a potential cure for genetic disorders that were
previously untreatable and could be a one-time treatment for many diseases.
However, there are still many challenges that need to be addressed before gene
therapy can become a mainstream treatment. With continued research and
development, it is likely that gene therapy will play an increasingly important
role in the future of medicine.
Gene Therapy Market
Dynamics:
The increasing
focus on gene therapy as a promising treatment for cancer and genetic diseases
has driven the growth of research in this area. As a result, companies are
launching new and advanced products to capitalize on opportunities in the gene
therapy market. Funding for gene therapy research is also on the rise, with
recent examples including a USD 12 million grant from the National Heart Lung
and Blood Institute to an Indiana University School of Medicine researcher in
March 2022 for exploring safer and potentially curative treatments for
hemophilia. Another example is Locana, Inc., which received USD 55 million in
Series A financing in May 2019 from existing investors such as ARCH Venture
Partners, Temasek, and Lightstone Ventures for its RNA-targeting gene therapy
pipeline programs.
Opportunities: Strong
Product Pipeline
The field of
gene therapy presents a promising avenue for revenue generation for
pharmaceutical and biotechnology companies. Key players in the industry are
currently concentrating on the development of new gene therapy products to take
advantage of the growing market opportunities. These products are in various
stages of development, with some still in the pre-clinical phase while others
are undergoing clinical trials and expected to be approved in the near future.
Gene therapy companies are targeting a range of disease areas, including
hemophilia, Fabry disease, wet age-related macular degeneration, and multiple
myeloma, which are expected to increase the patient pool for gene therapies.
Challenges: High Treatment
Cost
One of the
major challenges faced by the gene therapy industry is the high cost of
treatment. The cost of gene therapies can reach up to USD 1 million per
patient, depending on the disease condition. Although most gene therapy
products in the US and EU are covered under reimbursement programs, it is still
difficult for people who are not covered by insurance to afford such
treatments.
Non-Viral Vectors Segment
Dominates the Gene Therapy Market
The gene
therapy market is segmented into non-viral vectors and viral vectors based on
vectors. Non-viral vectors held the largest market share in 2021. The growth of
this segment is being driven by factors such as the lower immunogenicity of
non-viral vectors in comparison to viral vectors and the ease of mass
production.
In 2021, the
largest share of the global gene therapy industry was attributed to North
America. This can be attributed to the considerable investments made by both
the government and private sectors to develop more advanced gene therapy
products. Furthermore, the high adoption rate of these products in the region
and the presence of key market players also contribute to the significant
market share of North America in the global gene therapy market.
Market Segmentation
For the purpose
of this report, the global gene therapy market segmented on the basis of vectors
type, indication type, gene type, delivery method and region:
Vectors Type Outlook:
On the basis of
vectors type, the market is segmented into non-viral vectors, viral vectors. Further,
non-viral vectors is segmented into oligonucleotides, other non-viral vectors. Further,
viral vectors is segmented into retro viral vectors, adeno-associated virus
vectors, other viral vectors.
Indication Type Outlook:
On the basis of
Indication Type, the market is segmented into Neurological Diseases, Cancer,
DMD (Duchenne Muscular Dystrophy), Hepatological Diseases, Other Indications.
Gene Type Outlook:
On the basis of
Gene Type, the market is segmented into Antigen, Cytokine, Tumor Suppressor,
Suicide, Deficiency, Growth factors, Receptors, Others.
Figure 1 Gene Therapy Market By Gene Type
(Market Size And Forecast By Value - USD Million, 2022 & 2030)